Japan Medical Dynamic Marketing, INC.
Earnings Presentation First Half of Fiscal Year Ending March 2027
Consolidated revenue for the first half was 10,437 million yen (YoY -10.1%), and operating loss widened to -103.6 hundred million yen. The primary causes were revenue decline and cost deterioration in the U.S. market. Full-year forecasts were revised and the year-end dividend was changed from 17 yen to no dividend. The company will promote structural reforms and growth strategies, concentrating resources on key areas in Japan and the U.S.
Key Figures
- First half revenue for fiscal year ending March 2027: 10,437 million yen
- First half operating profit (loss) for fiscal year ending March 2027: -103.6 hundred million yen
- Full-year revenue forecast for fiscal year ending March 2027: 21,700 million yen
AI要約
Performance Overview
Consolidated revenue for the first half of the fiscal year ending March 2027 was 10,437 million yen (YoY -10.1%), and operating profit deteriorated to an operating loss of -103.6 hundred million yen. Gross profit declined due to reduced sales in the U.S. market and worsening manufacturing costs. Although SG&A cost controls were implemented, the decline in revenue and cost deterioration could not be offset, resulting in a substantial operating loss. A net loss attributable to owners of the parent was recorded for the interim period.
Outlook and Shareholder Returns
The full-year earnings guidance for the fiscal year ending March 2027 was revised considering weak second-half sales and delays in new product launches. The year-end dividend was revised from 17 yen to 0 yen to prioritize financial stabilization. The company will advance structural reforms and growth strategies in an integrated manner and continue investing in priority areas in Japan and the U.S.
Revenue Trend
Operating Profit Trend
Revenue by Major Product
Cost of Sales Ratio and SG&A Trend
Japan Medical Dynamic Marketing, INC.
Company overview · Stock price · Financial data · All IR
